{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:27:24Z","timestamp":1761863244107},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T00:00:00Z","timestamp":1381708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0077390","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T20:59:37Z","timestamp":1381784377000},"page":"e77390","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells"],"prefix":"10.1371","volume":"8","author":[{"given":"Octavian","family":"Bucur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea Lucia","family":"Stancu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Goganau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefana Maria","family":"Petrescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodvael","family":"Pennarun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Bertomeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya","family":"Khosravi-Far","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,10,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-09-0605","article-title":"Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors","volume":"69","author":"Z Jagani","year":"2009","journal-title":"Cancer Res"},{"key":"ref2","first-page":"63","article-title":"FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis","volume":"1785","author":"Z Jagani","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/leu.2012.222","article-title":"Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors","volume":"27","author":"FU W\u00f6hrle","year":"2013","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood-2003-12-4121","article-title":"Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr\/Abl-dependent and -independent mechanisms","volume":"104","author":"Y Dai","year":"2004","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrclinonc.2012.226","article-title":"Haematology: Ponatinib-the next TKI challenge","volume":"10","author":"M Razzak","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4161\/cbt.11.6.14675","article-title":"Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker","volume":"11","author":"R Dewar","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"ref7"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2011.06.004","article-title":"Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase","volume":"11","author":"FP Santos","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref9","first-page":"5106","article-title":"Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase\/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells","volume":"61","author":"Y Dai","year":"2001","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1158\/1535-7163.MCT-10-0944","article-title":"Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach","volume":"10","author":"JM Mehnert","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5021\/ad.2011.23.4.504","article-title":"Treatment of Disseminated Classic Type of Kaposi&apos;s Sarcoma with Paclitaxel","volume":"23","author":"SY Kim","year":"2011","journal-title":"Ann Dermatol"},{"key":"ref12","first-page":"2118","article-title":"Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr\/Abl+ human myeloid leukemia cells","volume":"63","author":"C Yu","year":"2003","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s10495-005-2490-y","article-title":"Sensitization of prostate carcinoma cells to Apo2L\/TRAIL by a Bcl-2 family protein inhibitor","volume":"10","author":"S Ray","year":"2005","journal-title":"Apoptosis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1091\/mbc.E09-09-0795","article-title":"Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT","volume":"21","author":"A Singh","year":"2010","journal-title":"Mol Cell Biol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<527::AID-IJC14>3.0.CO;2-#","article-title":"Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation","volume":"85","author":"RM Gangemi","year":"2000","journal-title":"Int J Cancer"},{"key":"ref17","first-page":"e263","article-title":"Analysis of apoptosis methods recently used in Cancer Research and Cell Death &amp; Disease publications. Cell Death","volume":"3","author":"O Bucur","year":"2012","journal-title":"Drosophila Inf Serv"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.1158\/0008-5472.CAN-10-0607","article-title":"A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors","volume":"70","author":"JH Seo","year":"2010","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"J Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1038\/sj.onc.1206607","article-title":"Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells","volume":"22","author":"P Coppo","year":"2003","journal-title":"Oncogene"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"NN Bewry","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"G Wei","year":"2010","journal-title":"Hematol Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-09-2181","article-title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536","volume":"70","author":"KV Gleixner","year":"2010","journal-title":"Cancer Res"},{"key":"ref24","first-page":"1191","article-title":"Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center","volume":"1","author":"KA Hotchkiss","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"IE Wertz","year":"2011","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"J Wu","year":"2008","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","article-title":"The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr\/abl","volume":"99","author":"Y He","year":"2002","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20020519","article-title":"Crosstalk between BCR\/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells","volume":"196","author":"A Ptasznik","year":"2002","journal-title":"J Exp Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1073\/pnas.0731871100","article-title":"Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor","volume":"100","author":"S Ghaffari","year":"2003","journal-title":"Proc Natl Acad Sci U_S_A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"O Hantschel","year":"2012","journal-title":"Nat Chem Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e7439","DOI":"10.1371\/journal.pone.0007439","article-title":"A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice","volume":"4","author":"KJ Johnson","year":"2009","journal-title":"PLOS ONE"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.leu.2401010","article-title":"Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR\/ABL-transformed cells","volume":"12","author":"M Sattler","year":"1998","journal-title":"Leukemia"},{"key":"ref33","first-page":"1398","article-title":"Crkl enhances leukemogenesis in BCR\/ABL P190 transgenic mice","volume":"61","author":"B Hemmeryckx","year":"2001","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"37525","DOI":"10.1074\/jbc.274.53.37525","article-title":"The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration","volume":"274","author":"N Uemura","year":"1999","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"R Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"ref36","first-page":"5761","article-title":"Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin","volume":"62","author":"R Nimmanapalli","year":"2002","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Y Wang","year":"2007","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V99.2.664","article-title":"Effects of the Bcr\/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro","volume":"99","author":"BM Mow","year":"2002","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"C Yu","year":"2003","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1038\/onc.2011.156","article-title":"NF-\u03baB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death","volume":"30","author":"SJ Stein","year":"2011","journal-title":"Oncogene"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2012.08.031","article-title":"Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK\/CHOP\/DR5 signaling pathway","volume":"329","author":"A Gopalan","year":"2013","journal-title":"Cancer Lett"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.21707","article-title":"Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities","volume":"104","author":"J Plati","year":"2008","journal-title":"J Cell Biochem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2741\/1903","article-title":"APO2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy","volume":"11","author":"O Bucur","year":"2006","journal-title":"Front Biosci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4020-6554-5_4","article-title":"Apoptotic pathways in tumor progression and therapy","volume":"615","author":"A Melet","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1039\/c0ib00144a","article-title":"Apoptotic cell signaling in cancer progression and therapy","volume":"3","author":"J Plati","year":"2011","journal-title":"Integr Biol (Camb)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.exphem.2008.10.013","article-title":"Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells","volume":"37","author":"S Myssina","year":"2009","journal-title":"Exp Hematol"},{"key":"ref47","first-page":"1313","article-title":"Novel strategies in the treatment of castration-resistant prostate cancer","volume":"40","author":"I Marech","year":"2012","journal-title":"Int J Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1179\/102453312X13336169156014","article-title":"New developments in the management of diffuse large B-cell lymphoma","volume":"17","author":"TM Habermann","year":"2012","journal-title":"Hematology"},{"key":"ref49"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"HJ Khoury","year":"2012","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"J Cortes","year":"2012","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/leu.2012.81","article-title":"Mast cells promote the growth of Hodgkin&apos;s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib","volume":"26","author":"H Mizuno","year":"2012","journal-title":"Leukemia"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"K Podar","year":"2009","journal-title":"Leukemia"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","article-title":"The tumor microenvironment is a dominant force in multidrug resistance","volume":"15","author":"AL Correia","year":"2012","journal-title":"Drug Resist Update"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.cellsig.2012.05.015","article-title":"Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment","volume":"24","author":"PF Seke Etet","year":"2012","journal-title":"Cell Signal"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nm.2831","article-title":"The secrets of the bone marrow niche: Metabolic priming for AML","volume":"18","author":"RZ Yusuf","year":"2012","journal-title":"Nat Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood-2008-07-167189","article-title":"ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines","volume":"113","author":"V Nardi","year":"2009","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0077390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T20:40:14Z","timestamp":1564519214000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0077390"}},"subtitle":[],"editor":[{"given":"Ramani","family":"Ramchandran","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,14]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0077390","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,14]]}}}